Cost Saving Analysis of Implementing Subcutaneous Formulation of Atezolizumab in a Danish Context (CS-ASSIST)

Speaker(s)

Beck C1, Fanoe A2, Bjerrum A3, Aller ML3, Lassen UN3
1Roche Pharmaceuticals AS, Copenhagen, 84, Denmark, 2Roche Pharmaceuticals AS, Copenhagen, Capital Region, Denmark, 3Rigshospitalet, Copenhagen, Denmark

Presentation Documents

OBJECTIVES: A subcutaneous (SC) administration of immunotherapy might offer a more time-efficient clinical setup. Capacity is a major focus area within Danish publicly funded healthcare. The objective was to analyze the potential cost and resource savings of using SC administration instead of an intravenous (IV) of atezolizumab in a Danish hospital outpatient setting.

METHODS: Two scenarios were constructed, one for IV and one for SC administration at a hospital outpatient setting. These two scenarios were compared based on total economic costs and time expenditure. In the analysis, all direct and indirect costs, from the pharmacy level to the patient leaving the hospital after treatment, were estimated, quantified, and compared. The assumptions for time and cost associated with IV and SC administration were derived from atezolizumab's Summary of Product Characteristics, the Danish health technology assessment organization cost analysis, IMscin001 study, and real-world data from the Danish Hospital Medicines Registry. To align with local clinical practices relevant healthcare professionals (HCPs) validated the assumptions

RESULTS: In a Danish hospital outpatient setting, a complete treatment course of atezolizumab per patient (excluding the cost of atezolizumab) administered intravenously requires 18.6 hours of HCP time and 933 euros, while subcutaneous administration requires 6.4 hours of HCP time and 620 euros. Using a SC formulation instead of an IV formulation can reduce HCP time by 12.2 hours per patient and lower costs by 313 euros. Annually, 800 patients with non-small cell lung cancer in Denmark are eligible for mono- immunotherapy. Implementing a SC formulation of atezolizumab could give a saving of 9,760 HCP hours and 250,400 euros compared with IV formulation.

CONCLUSIONS: Implementing SC administration of atezolizumab in a hospital outpatient setting has the potential to free up resources and increase capacity by reducing the number of hours spent by HCPs, while simultaneously lowering economic costs.

Code

EE20

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis, Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Oncology